Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Randomized Controlled Trial
100%
Diabetic Neuropathy
100%
Recombinant Human Nerve Growth Factor
100%
Adverse Events
22%
Placebo
22%
Patient Benefit
22%
Phase I Trial
22%
Significant Benefit
22%
Symptom Assessment
22%
United States
11%
Nerve Growth Factor
11%
Diabetes
11%
Phase II Trial
11%
Neuropathy Disability Score
11%
Neuropathy
11%
Nerve Conduction Studies
11%
Peripheral Neuropathy
11%
Randomized Double-blind
11%
Placebo-controlled
11%
Beneficial Effects
11%
Peripheral Nervous System
11%
Neurotrophic Factors
11%
Lower Limb
11%
Sensory Neurons
11%
Foot Ulcer
11%
Sympathetic Neurons
11%
Subcutaneous Injection
11%
Primary Outcome Measure
11%
P Factor
11%
Small Fibers
11%
Quantitative Sensory Testing
11%
Pain Severity
11%
Outpatient Center
11%
Injection Pain
11%
Sensory Polyneuropathy
11%
Hyperalgesia
11%
Plantar Foot
11%
Pain Syndrome
11%
Phase 3 Trial
11%
Control Phase
11%
Neuropathy Symptoms
11%
Secondary Outcome Measures
11%
Type 1 or Type 2 Diabetes
11%
Nursing and Health Professions
Diabetic Neuropathy
100%
Recombinant Nerve Growth Factor
100%
Efficacy
100%
Accident Prevention
100%
Neuropathy
44%
Placebo
33%
Adverse Event
22%
Symptom Assessment
22%
Clinical Trial
22%
Patient Benefit
22%
Outpatient
11%
Experimental Model
11%
Pain
11%
Foot Ulcer
11%
Subcutaneous Injection
11%
Polyneuropathy
11%
Hyperalgesia
11%
Nerve Growth Factor
11%
Injection Site Pain
11%
Neurotrophic Factor
11%
Maturity Onset Diabetes of the Young
11%
Neuroscience
Diabetic Neuropathy
100%
Randomized Controlled Trial
100%
Recombinant Nerve Growth Factor
100%
Neuropathy
44%
Placebo
33%
Nerve Growth Factor
11%
Peripheral Nervous System
11%
Neurotrophic Factor
11%
Sensory Neuron
11%
Polyneuropathy
11%
Nerve Conduction Study
11%
Hyperalgesia
11%